Clinical Trial Update: Triple Combination Therapy (ARNI, SGLT2i, MRA) in Advanced HFpEF [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating a triple therapy comprising an ARNI, an SGLT2 inhibitor, and a mineralocorticoid receptor antagonist for advanced heart failure wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction
• Left Ventricular Diastolic Dysfunction
• Myocardial Fibrosis

Drugs mentioned

• ARNI (sacubitril/valsartan) (sacubitril/valsartan)
• Mineralocorticoid receptor antagonist (finerenone) (finerenone)
• SGLT2 inhibitor (dapagliflozin) (dapagliflozin)

Snippet

Sponsor: National Medical Research Center for Cardiology, Ministry of Health of Russian Federation | Conditions: HFpEF, LVDD | Phase 2 | Status: RECRUITING